榮昌生物AH股走高 泰它西普初步數據結果達到主要終點
格隆匯9月20日丨榮昌生物A股漲6.99%,報49.56元;港股漲4.4%,報39.15港元。該公司昨日盤後發佈公吿,公司已完成了泰它西普(商品名:泰愛)在中國治療系統性紅斑狼瘡(SLE)的III期驗證性研究,並獲得了初步數據結果。全分析集(FAS)的初步結果顯示,給予泰它西普的患者在第52周的SRI-4(系統性紅斑狼瘡反應指數4)反應率明顯高於給予安慰劑的患者(82.6%對38.1%,p<0.001)。所有敏感度分析結果顯示,給予泰它西普的患者的SRI-4反應率明顯高於給予安慰劑的患者(p<0.001)。此研究達到其主要終點SRI-4。公司現正就泰它西普用於治療自身免疫性疾病領域的其他多種適應症開展II期或III期臨牀試驗,試圖解決該治療領域大量未滿足或未充分滿足的醫療需求。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.